Activities of atazanavir (BMS-232632) against a large panel of human immunodeficiency virus type 1 clinical isolates resistant to one or more approved protease inhibitors

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 4, 2003, Pages 1324-1333

  Colonno, Richard J ^a,c   Thiry, Alexandra ^a   Limoli, Kay ^b   Parkin, Neil ^b  

^a BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

^b MONOGRAM BIOSCIENCES   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ATAZANAVIR; INDINAVIR; LOPINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ARTICLE; CROSS RESISTANCE; DRUG ACTIVITY; DRUG MECHANISM; GENE MUTATION; GENOTYPE; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; VIRUS ISOLATION;

AMINO ACID SUBSTITUTION; DRUG RESISTANCE, MULTIPLE, VIRAL; GENOTYPE; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; OLIGOPEPTIDES; PYRIDINES;

EID: 0037379517     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.4.1324-1333.2003     Document Type: Article

References (35)

1. Angarano, G., and L. Monno. 2000. Genotype and phenotype resistance: an overview. J. Biol. Regul. Homeost. Agents 14:11-14.
2. Atkinson, B., J. Isaacson, M. Knowles, E. Mazabel, and A. K. Patick. 2000. Correlation between human immunodeficiency virus genotypic resistance and virologic response in patients receiving nelfinavir monotherapy or nelfinavir with lamivudine and zidovudine. J. Infect. Dis. 182:420-427.
3. Bally, F., R. Martinez, S. Peters, P. Sudre, and A. Telenti. 2000. Polymorphism of HIV type 1 gag p7/p1 and p1/p6 cleavage sites: clinical significance and implications for resistance to protease inhibitors. AIDS Res. Hum. Retroviruses 16:1209-1213.
4. Baxter, J. D., D. L. Mayers, D. N. Wentworth, J. D. Neaton, M. L. Hoover, M. A. Winters, S. B. Mannheimer, M. A. Thompson, D. I. Abrams, B. J. Brizz, J. P. Ioannidis, and T. C. Merigan. 2000. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS 14:F83-93.
5. Boden, D., A. Hurley, L. Zhang, Y. Cao, Y. Guo, E. Jones, J. Tsay, J. Ip, C. Farthing, K. Limoli, N. Parkin, and M. Markowitz. 1999. HIV-1 drug resistance in newly infected individuals. JAMA 282:1135-1141.
6. Clevenbergh, P., J. Durant, P. Halfon, P. del Giudice, V. Mondain, N. Montagne, J. M. Schapiro, C. A. B. Boucher, and P. Dellamonica. 2000. Persisting long-term benefit of genotype-guided treatment for HIV-infected patients failing HAART. The Viradapt study: week 48 follow-up. Antivir. Ther. 5:65-70.
7. Cohen, C. J., S. Hunt, M. Sension, C. Farthing, M. Conant, S. Jacobson, J. Nadler, W. Verbiest, K. Hertogs, M. Ames, A. R. Rinehart, and N. M. Graham. 2002. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS 16:579-588.
8. Colonno, R. J., J. Friborg, R. E. Rose, E. Lam, and N. Parkin. 2002. Identification of amino acid substitutions correlated with reduced atazanavir susceptibility in patients treated with atazanavir-containing regimens. Antiviral Ther. 7:S6.
9. Descamps, D., P. Flandre, V. Calvez, G. Peytavin, V. Meiffredy, G. Collin, C. Delaugerre, S. Robert-Delmas, B. Bazin, J. P. Aboulker, G. Pialoux, F. Raffi, and F. Brun-Vezinet. 2000. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilege (Agence Nationale de Recherches sur le SIDA 072 Study Team). JAMA 283:205-211.
10. Gehringer, H., J. R. Bogner, F. D. Goebel, H. Nitschko, and K. von der Helm. 2000. Sequence analysis of the HIV-1 protease coding region of 18 HIV-1-infected patients prior to HAART and possible implications on HAART. J. Clin. Virol 17:137-141.
11. Gong, Y. F., B. S. Robinson, R. E. Rose, Y. F. Gong, B. S. Robinson, R. E. Rose, C. Deminie, T. P. Spicer, D. Stock, R. J. Colonno, and P. F. Lin. 2000. In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632. Antimicrob. Agents Chemother. 44:2319-2326.
12. Havlir, D. V., N. S. Hellmann, C. J. Petropoulos, J. M. Whitcomb, A. C. Collier, M. S. Hirsch, P. Tebas, J. P. Sommadossi, and D. D. Richman. 2000. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. JAMA 283:229-234.
13. Hertogs, K., S. Bloor, S. D. Kemp, C. Van den Eynde, T. M. Alcorn, R. Pauwels, M. Van Houtte, S. Staszewski, V. Miller, and B. A. Larder. 2000. Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples. AIDS 14:1203-1210.
14. Hertogs, K., M. P. de Béthune, V. Miller, T. Ivens, P. Schel, A. Van Cauwenberge, C. Van Den Eynde, V. Van Gerwen, H. Azijn, M. Van Houtte, F. Peeters, S. Staszewski, M. Conant, S. Bloor, S. Kemp, B. Larder, and R. Pauwels. 1998. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob. Agents Chemother. 42:269-276.
15. Hertogs, K., S. Kemp, S. Bloor, K. Van Acker, J. Hansen, W. De Beukeleer, C. Roelant, B. Larder, and R. Pauwels. 1998. Comprehensive HIV drug resistance monitoring with rapid, high-throughput phenotypic and genotypic assays with correlative data analysis. AIDS (London) 12:S11.
16. Hirsch, M. S., F. Brun-Vezinet, R. T. D'Aquila, S. M. Hammer, V. A. Johnson, D. R. Kuritzkes, C. Loveday, J. W. Mellors, B. Clotet, B. Conway, L. M. Demeter, S. Vella, D. M. Jacobsen, and D. D. Richman. 2000. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA panel. JAMA 283:2417-2426.
17. Kantor, R., W. Fessel, J. Andrew, R. Zolopa, d. Israelski, N. Shulman, J. G. Montoya, M. Harbour, J. M. Schapiro, and R. W. Shafer. 2002. Evolution of primary protease inhibitor resistance mutations during protease inhibitor salvage therapy. Antimicrob. Agents Chemother. 46:1086-1092.
18. Karmochkine, M., A. Si Mohamed, C. Piketty, C. Ginsburg, G. Raguin, V. Schneider Fauveau, L. Gutmann, M. D. Kazatchkine, and L. Belec. 2000. The cumulative occurrence of resistance mutations in the HIV-1 protease gene is associated with failure of salvage therapy with ritonavir and saquinavir in protease inhibitor-experienced patients. Antiviral Res. 47:179-188.
19. Kempf, D. J., J. D. Isaacson, M. S. King, S. C. Brun, Y. Xu, K. Real, B. M. Bernstein, A. J. Japour, E. Sun, and R. A. Rode. 2001. Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients. J. Virol. 75:7462-7469.
20. Little, S. J. 2000. Transmission and prevalence of HIV resistance among treatment-naive subjects. Antivir. Ther. 5:33-40.
21. Little, S. J., E. S. Daar, R. T. D'Aquila, P. H. Keiser, E. Connick, J. M. Whitcomb, N. S. Hellmann, C. J. Petropoulos, L. Sutton, J. A. Pitt, E. S. Rosenberg, R. A. Koup, B. D. Walker, and D. D. Richman. 1999. Reduced antiretroviral drug susceptibility among patients with primary HIV infection. JAMA 282:1142-1149.
22. Markowitz, M., M. Conant, A. Hurley, R. Schluger, M. Duran, J. Peterkin, S. Chapman, A. Patick, A. Hendricks, G. J. Yuen, W. Hoskins, N. Clendeninn, and D. Ho. 1998. A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection. J. Infect. Dis. 177:1533-1540.
23. Martinez-Picado, J., A. V. Savara, L. Shi, L. Sutton, and R. T. D'Aquila. 2000. Fitness of human immunodeficiency virus type 1 protease inhibitor-selected single mutants. Virology 275:318-322.
24. Petropoulos, C. J., N. T. Parkin, K. L. Limoli, Y. S. Lie, T. Wrin, W. Huang, H. Tian, D. Smith, G. A. Winslow, D. J. Capon, and J. M. Whitcomb. 2000. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 44:920-928.
25. Pieniazek, D., M. Rayfield, D. J. Hu, J. Nkengasong, S. Z. Wiktor, R. Downing, B. Biryahwaho, T. Mastrob, A. Tanuri, V. Soriano, R. Lal, and T. Dondero. 2000. Protease sequences from HIV-1 group M subtypes A-H reveal distinct amino acid mutation patterns associated with protease resistance in protease inhibitor-naive individuals worldwide. HIV Variant Working Group. AIDS 14:1489-1495.
26. Qari, S. H., R. Respess, H. Weinstock, E. M. Beltrami, K. Hertogs, B. A. Larder, C. J. Petropoulos, N. Hellmann, and W. Heneine. 2002. Comparative analysis of two commercial phenotypic assays for drug susceptibility testing of human immunodeficiency virus type 1. J. Clin. Microbiol. 40:31-35.
27. Rabasseda, X., J. Silvestre, and J. Castañer. 1999. BMS-232632. Drugs Future 24:375-380.
28. Richman, D. D. 2000. Principles of HIV resistance testing and overview of assay performance characteristics. Antivir. Ther. 5:27-31.
29. Robinson, B. S., K. A. Riccardi, Y. F. Gong, Q. Guo, D. A. Stock, W. S. Blair, B. J. Terry, C. A. Deminie, F. Djang, R. J. Colonno, and P. F. Lin. 2000. BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents. Antimicrob. Agents Chemother. 44:2093-2099.
30. Rose, R. E., Y. F. Gong, J. A. Greytok, C. M. Bechtold, B. J. Terry, B. S. Robinson, M. Alam, R. J. Colonno, and P. F. Lin. 1996. Human immuno-deficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors. Proc. Natl. Acad. Sci. USA 93:1648-1653.
31. Schinazi, R. F., B. A. Larder, and J. W. Mellors. 2000. Mutations in retroviral genes associated with drug resistance: 2000-2001 update. Int. Antiviral News 8:65-91.
32. Schmidt, B., H. Walter, B. Moschik, C. Paatz, K. van Vaerenbergh, A.-M. Vandamme, M. Schmitt, T. Harrer, K. Uberla, and K. Korn. 2000. Simple algorithm derived from a geno-/phenotypic database to predict HIV-1 protease inhibitor resistance. AIDS 14:1731-1738.
33. Voelker, R. 2000. HIV drug resistance. JAMA 284:169.
34. Wegner, S. A., S. K. Brodine, J. R. Mascola, S. A. Tasker, R. A. Shaffer, M. J. Starkey, A. Barile, G. J. Martin, N. Aronson, W. W. Emmons, K. Stephan, S. Bloor, J. Vingerhoets, K. Hertogs, and B. Larder. 2000. Prevalence of genotypic and phenotypic resistance to antiretroviral drugs in a cohort of therapy-naive HIV-1 infected US military personnel. AIDS 14:1009-1015.
35. Winters, M. A., J. D. Baxter, D. L. Mayers, D. N. Wentworth, M. L. Hoover, J. D. Neaton, and T. C. Merigan. 2000. Frequency of antiretroviral drug resistance mutations in HIV-1 strains from patients failing triple drug regimens. The Terry Beirn Community Programs for Clinical Research on AIDS. Antivir. Ther. 5:57-63.